
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Lakewood-Amedex Biotherapeutics in a research report issued on Tuesday, November 17th. HC Wainwright analyst M. Keller anticipates that the company will post earnings per share of ($1.75) for the year. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is ($1.75) per share.
Other analysts have also issued reports about the company. Weiss Ratings upgraded Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Wall Street Zen downgraded shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lakewood-Amedex Biotherapeutics has a consensus rating of “Hold”.
Lakewood-Amedex Biotherapeutics Trading Up 15.0%
Shares of NASDAQ LABT opened at $0.24 on Friday. Lakewood-Amedex Biotherapeutics has a 52 week low of $0.17 and a 52 week high of $98.20. The company’s 50-day moving average price is $0.80 and its 200 day moving average price is $5.13. The stock has a market cap of $580,413.00 and a price-to-earnings ratio of -0.05.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.10).
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Featured Articles
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
